DISCOVER: A single-site double-blind placebo-controlled randomized mechanistic crossover trial to assess the influence of boDy weIght on aSpirin-triggered speCialized prO-resolVing mEdiatoRs
Brief description of study
This study employs a placebo-controlled randomized cross-over design to investigate the impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators in blood and neutrophils.
Clinical Study Identifier: s20-01884
ClinicalTrials.gov Identifier: NCT04697719
Principal Investigator:
Sean P. Heffron.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.